Related Experiment Video
Updated: Jun 25, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Biomarkers in heart failure
Manuel Garofalo1, Giorgia Panichella1, Alberto Aimo2
1Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
Advances in Clinical Chemistry
|June 23, 2026
Summary
Biomarkers are crucial for managing heart failure (HF), aiding diagnosis and prognosis. Novel biomarkers and AI integration promise personalized HF care, moving beyond traditional approaches for better patient outcomes.
Area of Science:
- Cardiology and Clinical Biomarker Research
- Translational Medicine and Precision Health
Background:
- Heart failure (HF) is a major global health burden with complex pathophysiology.
- Circulating biomarkers are vital for HF diagnosis, prognosis, and treatment guidance.
- Established biomarkers like BNP/NT-proBNP have limitations, necessitating research into novel markers.
Purpose of the Study:
- To review the evolving role of circulating biomarkers in heart failure management.
- To highlight established and emerging biomarkers and their pathophysiological relevance.
- To discuss the future potential of multimarker strategies and AI in personalized HF care.
Main Methods:
- Review of current literature on established and novel biomarkers in HF.
- Analysis of biomarker utility in diagnosis, prognostication, and therapeutic guidance.
- Exploration of emerging technologies like omics and AI for biomarker integration.
Main Results:
- BNP/NT-proBNP are cornerstones but influenced by clinical factors.
- Cardiac troponins and hsCRP offer prognostic insights into myocardial injury and inflammation.
- Novel biomarkers (Gal-3, sST2, GDF-15, MPO, MR-proADM) and non-coding RNAs provide incremental value.
- Multimarker strategies and AI show promise for refined risk stratification.
Conclusions:
- Biomarkers are essential pillars in modern heart failure care.
- Emerging biomarkers and advanced technologies are transforming HF management.
- The future of HF care lies in personalized, biomarker-guided strategies.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...